This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Sanofi Celebrates 50th Anniversary Of France - China Relations

PARIS, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today its participation in the commemoration of the 50 th anniversary of diplomatic relations between France and the People's Republic of China. In supporting the celebration, Sanofi affirms its commitment to economic development and public health in China.

"As one of the first multinational pharmaceutical companies to operate in China, Sanofi has continually provided innovative healthcare solutions for patients, expanding in pace with the country's development," said Christopher A. Viehbacher, Chief Executive Officer, Sanofi. "Our expanding portfolio of medicines and vaccines allows us to contribute to important public health issues in China, such as chronic disease management, prevention and food safety."

As one of the commemoration's major sponsors, Sanofi will participate in scientific events throughout the year in France and China, which will include Chinese students from select academic institutions in France. Sanofi also plans to participate in the "Better Healthcare" conference in Beijing with "Club Santé Chine", an initiative by the French government to help small and medium enterprises export healthcare products.

China is a showcase for Sanofi's collaborative approach, with many research and development agreements signed in the past six years, including in the areas of cancer, stem cells, diabetes and aging diseases. Sanofi partners include Shanghai Institutes for Biological Sciences, the Tianjin Institute of Hematology and Peking University. In recognition of the richness of China's research ecosystem, Sanofi settled management of its Asia-Pacific research and development activities in China in 2011.

About Sanofi in China Present in China since 1982, Sanofi is committed to the treatment of chronic diseases, including through programs on diabetes, cardiovascular diseases and rare diseases. The Group has 11 regional offices and seven factories producing medicines, vaccines, animal health and consumer health products. As a global leader in consumer healthcare, Sanofi signed a joint venture with Minsheng in 2010 and acquired BMP Sunstone in 2011. Sanofi generated € 1.2 billion in revenues in China in 2012, and employs 8,500 people.

About Sanofi Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contacts:  
Relations Presse Relations Investisseurs
Laurence Bollack Sébastien Martel
Tel +33 (1) 53 77 46 46 Tel +33 (1) 53 77 45 45  
mr@sanofi.com ir@sanofi.com

PDF Version http://hugin.info/152918/R/1757142/593602.pdf

HUG#1757142

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,031.14 +43.63 0.26%
S&P 500 1,984.13 -1.41 -0.07%
NASDAQ 4,518.9020 -48.6960 -1.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs